

Parand Darou Co.



Parand Darou
Pharmaceutical Co.

GMP

IR. FDA

www.paranddarou.co

Health Beyond Boundaries

Products Overview

API

Product	Standard	CAS. No
Buprenorphine HCl	USP , BP	53152-21-9
Naltrexone Hydrochloride	USP, BP	850808-02-5
Oxycodone Hydrochloride	USP, BP	124-90-3
Methadone Hydrochloride	USP, BP	1095-90-5
Noscapine	USP, BP, JP	128-62-1
Noscapine Hydrochloride	EP,BP, JP	912-60-7
Codeine phosphate hemihydrate	USP, BP	41444-62-6
Codeine	USP	76-57-3
Morphine Sulfate	USP, BP, IP	6211-15-0
Morphine Hydrochloride	EP, BP	6055-06-7
Papaverine Hydrochloride	USP, BP	61-25-6
Empagliflozin	In House	864070-44-0
Sitagliptin Phosphate	USP, BP	654671-77-9
Dapagliflozin Propanediol	USP	960404-48-2
Opium Tincture 1% Bulk	USP	8029-99-0

API

Intermediate

Products Overview



Product	Standard	CAS. No
Buprenorphine	In house	52485-79-7
Norbuprenorphine	In house	78715-23-8
3-O-Methyl Norbuprenorphine	In house	16614-59-8
Buprenorphine 3-O-Methyl Ether	In house	16524-65-5
Naltrexone	In house	16590-41-3
Naloxone	In house	465-65-6
Noroxymorphone Hydrochloride	In house	33522-95-1
Dihydrocodeine	In house	125-28-0
Oxymorphone	In house	76-41-5
Hydrocodone	In house	125-29-1
Papaverine Technical Grade	In house	58-74-2
Noscapine Technical Grade	In house	128-62-1
Morphine Technical Grade	In house	57-27-2
Codeine Technical Grade	In house	76-57-3

Products Overview

Product Name

Generic

PD Nosca

(Syrup)

Noscapin

Paxadone 325/5

(Tab)

Acetaminophen/Oxycodone
325/5

Paxadone 325/10

(Tab)

Acetaminophen/Oxycodone
325/10

Brudon 400/5

(Tab)

Ibuprofen/Oxycodone
400/5

Oxycodone 5

(Tab)

Oxycodone 15

(Tab)

Oxycodone 30

(Tab)

Opium Tincture 1%

(Syrup)



Finished

Product





Coming soon	Standard	CAS. No
Metocarbamol/ Ibuprofen	USP	CAS [532-03-6]
Tramadol 200 Sustained-Release (SR)	USP	CAS [532-03-6]
Buprenorphine 8/2/0.4 (Tab)		
Methadone 40/20 (Tab)		



Parand DarouPharmaceutical Co.

Parand Darou Pharmaceutical Company, as one of the leading knowledge-based companies in Iran pharmaceutical industry, has taken significant steps over the past three years toward sustainable development, technological innovation and an active presence in international markets. Established in 2006 with a specialized focus on the production of narcotic medicines. Parand Darou is now recognized as the second private company officially licensed by the Iran Food and Drug Administration to manufacture these products and now playing a vital role in advancing the country's pharmaceutical sector.

During the past three years, the company has achieved exports exceeding five million USD, successfully entering markets such as China, Russia, Chile, Kenya, India, El Salvador, Iraq and Nigeria. while also obtaining GMP certification for its knowledge-based production lines. These milestones have established Parand Darou as a prominent producer and exporter of narcotic pharmaceuticals. In line with its forward-looking vision, Parand Darou is continuing to expand active pharmaceutical ingredient (API) production lines, diversify its product portfolio and execute precise planning for the launch of 27 new formulations. While is Committed to professional ethics, innovation, integrity and social responsibility, dedicated to safeguarding public health, improving quality of life, and protecting the environment. With the acquisition of Parand Darou's managerial shares by Kimyagaran Emrooz Chemical Industries, a knowledge-based enterprise, the company has placed synergy of knowledge and expertise at the core of its progressive journey.

Address: Parand Darou Co., 2nd Karegar St., Karegar Blvd., Azadegan St., Imam Khomeini Blvd., Kaveh Industrial City, Saveh-Iran, Postal Code:3914319783

Phone: +98-21-92001602 - +98-21-92001601

Website: www.Paranddarou.co

Email: info@Paranddarou.co
commercialmanager@paranddarou.co

